Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...

Lucid Capital Markets is acting as the sole book-running manager for the proposed offering.

Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed ...

Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, ...

TME Pharma continues its active discussions with potential partners for the NOX-A12 program. TME Pharma has kept the clinical trial for glioblastoma open so that it can be resumed as soon as a ...

TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the de ...

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 ...

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.